NCT04668690View on ClinicalTrials.gov

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

193

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG

Mitoxantrone Hydrochloride Liposome Injection

Drug: Liposomal mitoxantrone hydrochloride (20 mg/m2) administered as an intravenous infusion on day 1 of each 28-day cycle.

DRUG

Chidamide

Drug: Chidamide tablet (30 mg) is given to the patients p.o. 30 minutes after breakfast, twice per week with 3-day intervals.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT04668690 - Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL | Biotech Hunter | Biotech Hunter